Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

WVE 10.16.2024

Full Press ReleaseSEC FilingsOur WVE Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
  • 12.23.2024 - Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity

CAMBRIDGE, Mass.,Oct. 16, 2024(GLOBE NEWSWIRE) --Wave Life Sciences Ltd.(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it will host a virtual Research Day onWednesday, October 30, 2024at10:00 a.m. ET(until11:30 a.m. ET).

During the event, Wave will provide an update on its rapidly advancing, wholly owned pipeline, introduce new GalNAc-conjugated RNA editing and siRNA programs, and discuss its clinically validated discovery and drug development platform, including its novel chemistry innovations enabling best-in-class potency, durability and delivery. The new RNA editing programs build on the learnings of WVE-006, Wave’s GalNAc-conjugated RNA editing oligonucleotide being advanced in the clinic for the treatment of alpha-1 antitrypsin deficiency – the first ADAR editing therapeutic to enter clinical development.

Wave will also highlight the opportunity for WVE-007, Wave’s GalNAc-siRNA INHBE candidate, as a novel obesity treatment, share new preclinical data, and discuss the differentiated profile of WVE-007. The event will feature perspectives from a key opinion leader in obesity,Mehmet Furkan Burak, MD, who will discuss the current treatment landscape for obesity and the unmet needs that remain.Dr. Burakis an Instructor in Medicine atHarvard Medical School(Endocrinology, Diabetes, and Hypertension) and an endocrinologist and obesity specialist at Brigham andWomen's Hospital Center for Weight Management and Wellness.

Wave’s Virtual Research DayA webcast of the event can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website:https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the event can join the audio-conferencing linkavailable here. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life SciencesWave Life Sciences(Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered inCambridge, MA.For more information on Wave’s science, pipeline and people, please visitwww.wavelifesciences.comand follow Wave onX(formerly Twitter) andLinkedIn.

Investor Contact:Kate Rausch+1 617-949-4827krausch@wavelifesci.com

Media Contact:Alicia Suter+1 617-949-4817asuter@wavelifesci.com

Primary Logo

Source: Wave Life Sciences USA, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com